Background Genetic determinants of stroke, the leading neurological cause of death and disability, are poorly understood and have seldom been explored in the general population. Our aim was to identify additional loci for stroke by conducting a meta-analysis of genome wide association studies.
Summary
Background Genetic determinants of stroke, the leading neurological cause of death and disability, are poorly understood and have seldom been explored in the general population. Our aim was to identify additional loci for stroke by conducting a meta-analysis of genome wide association studies.
Methods
We performed a genome-wide screen for common genetic variants associated with incident stroke risk in 18 prospective population-based cohorts comprising 84,961 participants, of whom 4,348 experienced stroke. Stroke (as per WHO definition) was ascertained and validated prospectively by study investigators. Mean age at stroke ranged between 45·8 and 76·4 years in the cohorts, and data collection took place between 1948 and 2013. We followedup variants yielding an association at p<5×10 -6 with all stroke, ischemic stroke, cardioembolic, or non-cardioembolic ischemic stroke in the largest available cross-sectional studies (70,804 participants of whom 19,816 experienced stroke). Summary-level results of discovery and follow-up stages were combined using inverse variance-weighted fixed-effects meta-analysis and look-up was performed in stroke sub-types. For genome-wide significant findings (p<5×10 -8 ), we explored associations with additional cerebrovascular phenotypes and undertook functional analyses by conditional (inducible) deletion of the likely causal gene in mouse and also studied the expression of the latter and effects on cerebral vasculature in zebrafish mutants.
Findings We replicated seven of eight known loci for ischemic stroke and identified a novel locus at chr6p25 (rs12204590, near FOXF2) associated with risk of all stroke (odds ratio [OR] = 1·08, 95% CI 1·05-1·12, p=1·48×10 -8 [minor allele frequency 21%]). The rs12204590 stroke risk allele also increased MRI-defined white matter hyperintensity (WMH) burden, a marker of cerebral small artery disease, in stroke-free adults (N=21,079; p=0·0025). Consistently, young patients (age range 2-32 years) with segmental deletions of FOXF2 exhibited extensive WMH burden. Deletion of Foxf2 in adult mice resulted in cerebral infarction, reactive gliosis, and microhemorrhage. The zebrafish equivalents of FOXF2 (orthologs) foxf2b/foxf2a were expressed in brain pericytes and mutant foxf2b-/-cerebral vessels showed decreased smooth muscle cell and pericyte coverage.
Interpretation In our study of 155,765 persons in total (24, 164 with stroke), we identified common variants near FOXF2 associated with increased stroke susceptibility. Extensive epidemiological and experimental data suggest that FOXF2 mediates this association, potentially via differentiation defects of cerebral vascular mural cells. Further expression studies in appropriate human (including fetal) tissues and further functional experiments with longer follow-up periods are required to fully understand the underlying mechanisms.
Funding NIH, NHMRC, CIHR, European national research institutions, Fondation Leducq

Research in context Evidence before this study
Stroke is the leading neurological cause of death and disability worldwide. A substantial proportion of stroke risk remains unexplained, and a contribution of genetic factors is supported by recent discoveries of common genetic variants associated with stroke risk, identified through large, collaborative, genome-wide association studies (GWAS). However, most of these showed association with cardioembolic and large artery ischemic stroke and no robust genetic association has been reported for other subtypes, especially the very common but poorly understood small artery ischemic stroke. Genetic associations with all stroke are also scarce, with only few genetic studies looking comprehensively at incident stroke in a population-based longitudinal setting.
Added value of this study
This study is novel by several aspects. First, leveraging on extensive phenotypic and genotypic information from very large population-based and hospital-based studies we identified a novel risk locus for stroke that appears to be mediated by small artery disease. Although small artery disease is one of the major subtypes of stroke, GWAS have failed so far to discover risk loci for small artery ischemic stroke (except for an association with the PRKCH locus identified in a Japanese study, which was not found in European populations). Second, while GWAS have successfully identified numerous genetic associations with complex diseases, including stroke, biological mechanisms underlying these associations still remain elusive for most of the variants, precluding any clinical applications beyond risk prediction. Here we provide important preliminary experimental evidence from zebrafish and mouse models that the observed statistical association reflects an effect of the nearby transcription factor FOXF2 (a gene predominantly expressed in fetal tissue), on the development of cerebral vasculature. Conditional deletion of Foxf2 in adult mice led to cerebral infarction, reactive gliosis and, to a lesser extent, microhemorrhage. In zebrafish foxf2b -/-zebrafish mutants showed decreased smooth muscle cell and pericyte coverage. Third, we show that patients with a rare monogenic ophthalmologic condition due to segmental deletions encompassing FOXF2 also exhibit features of cerebral small artery disease, providing an example of how monogenic conditions can inform the mechanisms of complex diseases.
Implications of all the available evidence
The present findings provide important novel insight into the genetic underpinnings of stroke, especially of the small artery subtype, with strong evidence from multiple approaches for a pivotal role of FOXF2, a neural crest expressed transcription factor involved in cerebral vessel development. Cerebral small artery disease is a major, but poorly understood, cause of stroke in all ethnic groups, and "subclinical" small artery disease (here also showing association with the stroke risk variants near FOXF2) has been associated with progressive functional and cognitive decline and increased risk of dementia. Currently no mechanism-based treatment is available for small artery disease, other than management of risk factors. The present findings provide promising grounds for follow-up, pointing to a possible novel mechanism of stroke and small artery disease. Further research is warranted to explore whether this can translate into clinical applications.
Introduction
Stroke represents the leading neurological cause of death and disability worldwide.
1 A substantial proportion of stroke risk remains unexplained, and a contribution of genetic factors is supported by recent discoveries of common genetic variation associated with stroke risk, identified through large, collaborative, genome-wide association studies (GWAS). 2 These studies have estimated the proportion of phenotype variance explained by the genome-wide genotypes to range between 16-40% for ischemic stroke and between 34-73% for intracerebral hemorrhage. 3 Most associations to date have been specific to certain ischemic or hemorrhagic stroke types, although a few risk loci for overall ischemic stroke (IS) have also been reported. 2 Overall, the search for stroke loci has been less successful than for other complex phenotypes. 4 Potential explanations include heterogeneity of stroke and also limited ability to detect genetic variants increasing both stroke risk and severity, due to the cross-sectional design of most studies, with hospital-based case ascertainment and non-inclusion of severe strokes with early mortality. Population-based cohort studies, with blood samples drawn at recruitment and prospective incident stroke ascertainment, offer the advantage of including severe strokes leading to early death.
We performed a genome-wide screen for common genetic variants associated with an increased risk of incident stroke in prospective population-based cohort studies and followed up these results in the largest available cross-sectional studies. Detailed functional exploration of novel genome-wide significant association was conducted in zebrafish and mice.
Methods
Study population for discovery GWAS
The GWAS of incident stroke comprised 84,961 participants of European origin from 18 community-based prospective cohort studies participating in the Cohorts of Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. All participants were free of stroke at baseline and 4,348 developed incident stroke during 10 years of average follow-up (table 1, appendix). Some but not all of the cohorts included in the present analysis (representing <1,544 incident stroke cases) have participated in published HapMap-based stroke GWAS. 5, 6 The study was approved by the ethics committee of the participating studies and written informed consent was obtained by all study participants.
Stroke definition and classification of subtypes
Stroke was defined as a focal neurologic deficit of presumed vascular origin with sudden onset and lasting for >24 hours, or until death if the participant died <24 hours after onset of symptoms. Strokes were classified as IS (N=3,028), intracerebral hemorrhage (ICH, N=277), or unknown type based on clinical and imaging criteria; for cohorts where IS subtypes were available (Table 1) , IS was subdivided into cardioembolic (N=602) and non-cardioembolic (N=1,770) subtypes. Numbers were too small to analyze large artery IS (N=117) and small artery IS (N=87) separately in this discovery dataset. Subarachnoid hemorrhage was not considered due to distinct mechanisms and very small numbers. Detailed definitions of stroke types and subtypes are given in the appendix.
Genotyping and imputation
Genotyping platforms and quality control filters are described in supplementary tables 1-2. All but one study used imputed genotypes based on the 1000GpIv3 "All" reference panel (supplementary tables 3-4).
Genome-wide association analyses
Using genome-wide multivariable Cox regression, we tested associations of genetic variants with incident stroke (all stroke, IS, cardioembolic IS, non-cardioembolic IS, and in secondary analyses ICH) under an additive genetic model, adjusting for sex, age, and when relevant principal components of population stratification, study site, or familial structure (appendix, supplementary table 5). Meta-analysis of study-specific association statistics was performed at two sites (G.C. and A.Y.C.) using inverse-variance weighted meta-analysis with METAL (http://csg.sph.umich.edu/abecasis/Metal/). The QQ plots and values of the genomic inflation factor lambda suggest no systematic inflation of test statistics due to population stratification, cryptic relatedness, or technical artefacts (supplementary table 6 and supplementary figure 1). Power of the discovery stage to detect association with various stroke subtypes is presented in supplementary figure 2.
Follow-up of most significant genetic associations
We selected variants with high imputation accuracy (mean R 2 >0·80) yielding an association p<5×10 -6 with all stroke, IS, cardioembolic, or non-cardioembolic IS. In total 177 variants belonging to 21 loci (linkage disequilibrium [LD] r 2 >0·7 within each locus) were selected. In silico follow-up association analyses were performed in four independent cross-sectional studies, with mostly hospital-based stroke ascertainment, totaling 19,816 stroke patients (table  1) and 50,988 controls, from the Stroke genetics network (SiGN), 7, 8 METASTROKE, 6 Heart and Vascular Health 1 (HVH1), 9 and Cervical Artery Dissections and IS Patients (CADISP) studies. 10 Except for 4,963 African-American and 3,371 Hispanic participants (cases and controls) in SiGN, all follow-up samples were of European ancestry. Follow-up analyses were performed with the same, or most similar, phenotype as in discovery (table 1), using logistic regression under an additive genetic model, followed by inverse-variance weighted metaanalysis of study-specific association statistics (appendix).
After Bonferroni correction for the number of independent loci (r 2 <0.01 reflecting absence of linkage disequilibrium), p<2·38×10 -3 was considered significant evidence of replication. We did not correct for the number of stroke phenotypes (all stroke, IS, cardioembolic, and noncardioembolic IS) as they are not independent (the latter being subtypes of the former). Only loci reaching genome-wide significance, at p<5×10 -8 , in the combined meta-analysis of discovery and follow-up samples were given further consideration.
Secondary analyses
We examined the association of novel genome-wide significant all-stroke risk variants with stroke subtypes in CHARGE and follow-up samples (using TOAST subtyping 11 and in sensitivity analyses the Causative Classification System (CCS) implemented in SiGN 7, 8 ). We examined whether the same variants were associated with white matter hyperintensity (WMH) burden, a quantitative MRI-marker of cerebral small artery disease, in 21,079 communitydwelling participants, 12 and with ICH in an independent study comprising 1,576 patients (682 lobar, 894 deep ICH patients) and 1,303 controls of European ancestry. 13 We tested whether risk variants with genome-wide or suggestive association for all-stroke or IS in the populationbased discovery stage were associated with incident fatal and non-fatal stroke. We also looked for a significant association of these risk variants comparing fatal and non-fatal stroke, which would suggest different genetic influences in the two groups of cases, assuming systematic bias in follow-up does not influence the frequency of the candidate variant in either group.
Functional exploration of novel stroke risk locus
Based on in silico functional annotation (appendix) and literature review of the novel genomewide significant stroke risk locus identified by the aforementioned approach, we examined the effect of loss of function of the putative causal gene on brain vasculature and stroke-related phenotypes, in humans, mice, and zebrafish (appendix).
To complement the genome wide analysis, we utilized a rare cohort of Axenfeld-Rieger syndrome patients with deletions of the novel stroke risk locus to directly determine if loss of this locus resulted in more severe cerebro-vascular MRI phenotypes. By extracting data from individual MRI slices, we calculated the volume of WMH in two patients with large segmental deletions encompassing the putative causal gene (aged 2 and 32 years) and two patients with smaller deletions in whom this gene was intact (aged 15 and 17 years).
The putative causal gene was deleted in adult (12 weeks) conditional (floxed) mouse mutants by Cre-ERT2, an inducible Cre recombinase, as previously described, 14 and sacrificed six weeks later. Brains of conditional knockouts and controls were examined by histology (using hematoxylin/eosin or Richardson's methylene blue/Azure II) and glial fibrillary acidic protein (GFAP) immunofluorescence (DAKO Z0334), to search for features of vascular brain injury.
Zebrafish permit live imaging of blood vessel and mural cell interactions with exceptional clarity, using transgenic lines which permit in vivo visualization of endothelium and smooth muscle. Expression of the putative causal gene in the brain of zebrafish larvae was assessed by in situ hybridization, and compared to that of established pericyte markers, notch3, and pdgfrβ. 15 Function of FoxF2 was assessed by knockout using transcription activator-like effector nucleases (TALENs) to create targeted nonsense mutations in the DNA binding domain (supplementary figure 3 ). Smooth muscle cell coverage of branches of brain vessels was examined in live transgenic mutant and wild type zebrafish embryos; these cells were modified to express green fluorescent protein using the α-smooth muscle actin promoter (acta2:GFP) at 4-6 days post-fertilization. Pericyte density was assessed by pdgfrβ in situ hybridization.
Role of the funding source
The funder was involved in the study design but had no role in data collection.
Results
In the population-based discovery stage (4,348 stroke cases versus 80,613 controls) 177 genetic variants in 21 independent loci reached p<5×10 -6 in association with incident all-stroke, IS, cardioembolic, or non-cardioembolic IS (supplementary table 7). Eleven loci showed suggestive association at p<5×10 -6 with incident all-stroke or IS. Ten additional loci showed association at p<5×10 -6 with incident cardioembolic IS, one locus (lead-SNP rs72794386, in SLC12A2) showing genome-wide significance: HR=1·67 (95%CI:1·39-2·00), p=4·37×10 In the cross-sectional follow-up samples (19,816 stroke cases versus 50,988 controls) two loci replicated at p<2·38×10 -3 and reached genome-wide significance (p<5×10 -8 ) in the combined analysis (table 3) . The first one is a novel locus (chr6p25·3, lead SNP rs12204590), lying between FOXQ1 and FOXF2, showing association with incident all-stroke: combined OR=1·08(1·05-1·12), p=1·48×10 -8 (MAF=21%, figure 1 ). Associations in each study are shown in supplementary figure 5. The second (chr4q25, near PITX2) is a known risk locus for cardioembolic IS: combined OR=1·37(1·29-1·46), p=4·72×10 -24 for incident cardioembolic IS (MAF=12%). The SLC12A2 locus (genome-wide significant in the small cardioembolic IS discovery sample) did not show evidence of replication (p=0·27).
We also explored association of the chr6p25·3 locus with stroke subtypes. In the discovery sample, lead SNP rs12204590 was associated with incident IS: HR=1·13[1·06-1·20], p=1·64×10 -4 (non-cardioembolic IS: HR=1·12[1·04-1·22], p=4·35×10 -3 ; cardioembolic IS: HR=1·10[0·95-1·27], p=0·21). In follow-up samples, we observed association with small artery IS: OR=1·08[1·02-1·14], p=0·0094 for rs12200309 (in complete LD with rs12204590), using TOAST subtypes, while association with large artery and cardioembolic IS was non-significant (p>0·35). The association with small artery IS was even more marked when using CCScausative subtyping where available (SiGN): OR=1·11[1·05-1·18], p=0·00029 (supplementary  table 8 ). We also observed significant association of chr6p25·3 with increasing WMH burden in the general population (lowest p=0·0025, supplementary table 9). The HR for association of rs12204590 with incident fatal IS (n=271, HR=1·21[0·99-1·50], p=0·0684) was higher than with non-fatal IS (n=2300, HR=1·14[1·06-1·22], p=4·93×10 -4 ), but the difference was not statistically significant (supplementary tables 10-11). We did not observe any heterogeneity by ethnicity for associations between the chr6p25 locus and stroke risk (supplementary table 12 ).
The genomic region where the variant associated with increased stroke risk and adjacent linked variants (linkage disequilibrium r 2 >0.50) are located, appears to include enhancers (regions of DNA that activate transcription of nearby genes). This genomic region also includes DNAaseI hypersensitive regions, a marker of open chromatin associated with active cis-regulatory elements important for transcription of nearby genes (figure 1, appendix, supplementary tables 13-14). Two SNPs (rs7750826 and rs2006798, r2>0•75 with rs12204590) had RegulomeDB scores of "2b" suggesting a likely role in regulating gene expression (combination of transcription factor binding site, and DNAse peak and footprint, figure 1 and supplementary table 15). The genomic region that includes the lead variant and variants in LD with it includes two protein coding genes FOXQ1 and FOXF2. The same region also includes a microRNA (MIR6720). However if we expand the regional plot to a 1 MB region around the lead variant, the region also includes two other protein coding genes (FOXC1 and GMDS) and a long noncoding RNA (LINC01622) (figure 1). We performed an extensive search of publically available eQTL 16 and miRNA databases 17 , examined mRNA expression of FOXF2 and adjacent genes in dorsolateral prefrontal cortex of 508 persons enrolled in the Religious Orders Study and the Rush Memory and Aging Project, 18 and mined large sets of epigenomic data from the International Human Epigenome Consortium (www.ihec.org) (supplementary tables 16-17). Expression quantitative trait loci or methylation QTLs in this region were lacking, the only eQTL observed was for a long non-coding RNA (LOC285768) in the human brain (p=5·25×10 -7 for rs7746700, average in ten brain regions, http://www.braineac.org/). However, the different distribution of histone modifications associated with active genes in cells expressing FOXF2 or FOXQ1 suggested that these variants are likely to lie within the regulatory region of FOXF2 (supplementary figure 6) . Moreover, we observed lowest CpG methylation levels (indicating highest activity) at this locus in fetal brain as compared to any other tissue. 19 We have previously described that patients with Axenfeld-Rieger syndrome, a rare heterogeneous condition with maldevelopment of the ocular anterior segment, attributable to mutation or copy number variation of FOXC1, adjacent to FOXF2 on chr6p25, have increased burden of MRI-markers of cerebral small artery disease. 20 Within this cohort of FOXC1-attributable Axenfeld-Rieger syndrome we identified two patients with 300kb segmental deletions encompassing both FOXC1 and FOXF2 and found that they had extensive, confluent WMH, with more than ten-fold larger WMH volume than two patients with segmental deletions of FOXC1 only (30kb), although small numbers do not allow a formal statistical comparison. All patients were younger than 35 years (age range 2-32 years) and lacked vascular risk factors ( figure 2A-E, supplementary table 18 ). White matter hyperintensities are normally absent or negligible in this age-range in the general population.
17,21
We next used mice and zebrafish, two common model organisms for brain and vascular development, to show that disturbances of FoxF2 expression are associated with neurovascular pathology and vascular mural cell defects. We recently showed that murine Foxf2 is expressed in vascular mural cells, specifically in the central nervous system, and is essential for pericyte differentiation, vascular maturation and formation of the blood-brain barrier (BBB).
14 Moreover, we demonstrated that inactivation of Foxf2 in adult mice leads to gradual breakdown of the BBB and increased mortality. 14 To understand the mechanism at the tissue level we used histology of the brains from six mice six weeks after Foxf2 inactivation and found areas of neurons with pyknotic nuclei and eosinophilic cytoplasm (figure 2F-F''), suggestive of ischemic infarction, in five of the brains. Patches with elevated levels of glial fibrillary acidic protein (GFAP) in astrocytes (figure 2G) indicated reactive gliosis. Higher magnification revealed a few instances of microhemorrhage with extravascular ertythrocytes ( figure 2I ). In contrast, brains from control mice contained only occasional and scattered neurons that showed signs of apoptosis, or isolated astrocytes with increased GFAP immuonoreactivity, and no visible hemorrhagic lesions (figure 2H). Mice in which Foxf2 had been deleted had significantly higher mortality than control mice. Usually the animals were found dead, but some had to be euthanized after exhibiting behaviour indicative of brain damage, such as circling or lopsided gait.
In zebrafish we show that foxf2a and foxf2b (FOXF2 orthologs) are expressed in pericytes closely wrapping the cerebral endothelium, similar to mice ( figure 2J-K) . Expression occurs in a pattern similar to established pericyte markers, platelet derived growth factor receptor β (pdgfrβ), and notch3 (figure 2L-M). We made two zebrafish knockout lines foxf2b ca22 and foxf2b ca23 with nonsense mutations in the first exon of foxf2b that would result in a translation block prior to the essential DNA binding domain (supplementary figure 3) . Both alleles have identical phenotypes. foxf2b mutants had decreased expression of the brain pericyte marker pdgfrβ (Fig 2N-Q) suggesting pericyte maturation defects, and decreased acta2-positive smooth muscle cell coverage on large cerebral vessels suggestive of smooth muscle defects ( figure 2R-U, supplementary figure 7) . In homozygous mutants, acta2 was visible up to second order of cerebral vessel branching or less versus fourth or higher order branch in wildtype or heterozygous embryos.
Seven of eight risk loci for IS 2 identified in cross-sectional studies were associated with incident stroke in the population-based GWAS (discovery), predominantly in the same subtype as the original study (p-range=0·047-7·82×10 -5 , supplementary table 19). One risk locus for IS (PITX2) also showed association with incident ICH (p=0·0031), and one risk locus for ICH (PMF1-BGLAP), also a risk locus for increasing WMH burden, 12 was associated with incident IS (p=0·00064), both in the same direction (please see appendix for more details).
Discussion
In a large population-based GWAS meta-analysis of incident stroke, with follow-up in the largest available cross-sectional stroke GWAS, we identified a novel genome-wide significant association of common variants in the chr6p25·3 region, near FOXF2, with risk of stroke. Associations predominated with small artery IS, and significant association was observed with WMH burden; in addition, patients with rare segmental deletions of FOXF2 also showed extensive WMH burden. These findings suggest an effect of this locus on cerebral small artery disease, however the mechanism by which this transcription factor results in cerebral small artery disease and stroke is unclear. To support plausibility of FOXF2 we undertook experimental studies in two animal species to examine its role in cerebral vessel development and stability. We demonstrate areas of infarction and to a lesser extent microhemorrhages in brains of conditional Foxf2 mutant mice. We show in zebrafish that foxf2b is expressed in brain pericytes (as in mice 14 ) and that reduction in foxf2b function leads to differentiation defects of both pericytes and smooth muscle cells in the developing cerebral vasculature.
Converging evidence, both from the present work and previous publications, suggests an important role of Forkhead transcription factor 2 (FOXF2) in cerebrovascular disease. In mice, we recently showed that Foxf2 is required for brain pericyte differentiation and BBB development, with Foxf2 -/-embryos exhibiting thickened endothelium, perivascular edema, thinning of the vascular basal lamina, and leaky BBB. 14 We had also described that Foxf2 inactivation in adult mice results in endothelial thickening and BBB breakdown, 14 an important mediator of cerebral small artery disease, and increased mortality. 22 In this conditional Foxf2 mutant, we now analyzed mouse brains six weeks after Foxf2 inactivation and interestingly we observed signs of brain infarction, with reactive astrogliosis, and to a lesser extent microhemorrhages. Of note, in prior experiments Foxf2-/-mouse embryos were found to develop intracranial hemorrhage, 14 while areas of microhemorrhage were scarce in conditional Foxf2 mutant brains. We were also not able to demonstrate an association of the chr6p25.3 locus with intracerebral hemorrhage in the largest available collaborative genetic association study, although power may have been limited (supplementary table 20 ). In zebrafish, foxf2b knockout led to disruption of cerebral vasculature with decreased pericyte density and smooth muscle cell coverage (figure 2). Foxf2 is first expressed in the neural crest and in mice regulates pathways involved in mural cell (pericyte and vascular smooth muscle cell) differentiation including the pdgfβ and serum response factor pathways.
14, 23 We did not observe hemorrhage in the zebrafish foxf2 mutant model during embryonic stages. We note that we have knocked out only one of two foxf2 genes in fish and even though mural cell markers have changed expression in foxf2b mutants, there may be genetic compensation from the foxf2a gene that may make the phenotype less severe. However we have not found expression changes in foxf2a in foxf2b mutants. We cannot exclude haemorrhage occurring at juvenile or adult stages that we have not been able to examine. In summary our data suggest that association of FOXF2 and stroke may arise from differentiation defects of cerebral vascular mural cells. It is beyond the scope of this study, but demonstrating the cellular requirement for FoxF2 by expression under a vascular mural cell promoter for prevention of stroke and mural cell phenotypes in mutants is an important future experiment. No current promoters available in fish express in both smooth muscle and pericytes where we find foxf2 expression.
Forkhead transcription factors are involved in various developmental and biological processes, and tend to be distributed in clusters on the genome. 24, 25 The evolutionarily conserved chr6p25 cluster comprises FOXQ1, FOXF2, and FOXC1. Our lead stroke risk variants lie between FOXQ1 (22·4kb) and FOXF2 (52·7kb). In contrast with the compelling experimental evidence for a central role of FOXF2 in cerebrovascular disease, FOXQ1 has not been implicated in cerebrovascular phenotypes; mutant mice for this gene show mainly altered hair differentiation and gastric mucin secretion. 26, 27 The third gene in the cluster, FOXC1 (225kb downstream of FOXF2 and 273.3kb downstream of stroke risk variants), was also recently shown to be expressed in the brain vasculature and influence vessel morphogenesis, 28 and arteriovenous specification. 29 MRI analysis of patients with FOXC1-attributable Axenfeld-Rieger syndrome revealed MRI-features of cerebral small artery disease (including increased WMH burden), and genetic variants downstream of FOXC1 were associated with WMH burden in the general population. 20 These previously described variants are independent (r 2 <0·017) from the stroke risk variants near FOXF2 described here. 20, 30 This, together with the tenfold WMH burden in patients with segmental deletion of both FOXC1 and FOXF2 versus FOXC1 alone, suggests an independent role of FOXF2 in cerebral small artery disease. Differences in the roles of foxf2 and foxc1a/b are also seen in the zebrafish model. Knockdown of zebrafish foxc1a/b leads to embryonic cerebral hemorrhage in embryos, 31 while knockout of foxf2b at the same developmental stage, does not. foxc1a/b morphants showed unchanged pdgfrβ expression while foxf2b mutants show decreased pdgfrβ expression. We show that foxf2b mutants have cerebral smooth muscle defects while to date we have only examined ventral head smooth muscle defects in foxc1a/b morphants. Thus although the two genes are closely related, there are indications that their roles in vascular mural cells may be distinct.
Intriguingly, PITX2 (chr4q25), a known risk locus for cardioembolic IS and atrial fibrillation, 32,33 also genome-wide significant for cardioembolic IS in the present sample, encodes a neural crest-expressed transcription factor that physically interacts with FOXC1 and harbors causal mutations for Axenfeld-Rieger syndrome. 20 Variants near PITX2 were associated with WMH burden. 20, 30 In the present study, common variants near PITX2 were also associated with ICH risk, of which the main mechanism in the general population is small artery disease. 34 These observations suggest that FOXF2, FOXC1 and PITX2 could perhaps contribute to cerebrovascular disease via partly shared pathways, involving cerebral small arteries.
The relatively limited number of incident strokes (N=4,300), particularly stroke subtypes (N=602 for cardioembolic IS while small artery occlusion, large artery IS and other stroke subtypes had to be merged into a single category) may have hampered our ability to detect additional associations. We were also underpowered (<80% power) to detect associations with smaller effect sizes and lower allele frequencies (supplementary figure 2) . While there are strong arguments from the described animal experiments suggesting that FOXF2 is the causal gene underlying the observed genetic association with stroke and small artery disease at chr6p25, functional annotation of the identified risk variants is limited, with a lack of expression quantitative trait loci despite an extensive search of publicly available and other databases, possibly reflecting tissue specificity, or primarily developmental effects, as supported by higher expression of FOXF2 in fetal than adult brain (www.ihec.org) and lower methylation levels of the stroke risk locus in fetal versus adult tissues. Another limitation is that we only explored common variants and not rare variants in this region. In addition, we have used an additive genetic model only, the most powerful approach when the underlying genetic model is unknown, but we cannot exclude that associations with genetic risk loci following a recessive or dominant model may have been missed. Nevertheless, we confirmed and extended the range of associations for previously discovered stroke risk loci, in a population-based sample. For the first time we describe shared genetic variation underlying both IS and ICH (chr4q25, chr1q22), in agreement with some monogenic strokes having both ischemic and hemorrhagic phenotypes, mostly with underlying small artery disease. [35] [36] [37] The association we previously described between chr12p13 and incident stroke in a smaller, overlapping sample was also the most significant association with IS in the present population-based GWAS, 5 showing a stronger association with incident fatal versus non-fatal stroke, suggesting an effect on stroke survival (supplementary table 12 ).
In summary, we identified common variants near FOXF2 associated with increased stroke susceptibility, especially of the small artery subtype, and with extensive "subclinical" small artery disease. This is particularly interesting, as GWAS have failed so far in discovering risk loci for small artery IS (except for an association with the PRKCH locus identified in a Japanese study, which was not found in European populations). 6, 38 Brain imaging data from patients with rare segmental deletions encompassing FOXF2, and extensive functional experiments across evolutionarily separated species, suggest an important role of FOXF2 in cerebrovascular disease, especially cerebral small artery disease, possibly by affecting differentiation of cerebral vascular mural cells. Cerebral small artery disease is a major, but poorly understood, cause of stroke in all ethnic groups, and "subclinical" small artery disease has been associated with progressive functional and cognitive decline and increased risk of dementia. Currently no mechanism-based treatment is available, other than management of risk factors. The present findings provide promising grounds for follow-up, pointing to a possible novel mechanism of stroke and small artery disease. Further research is warranted to explore whether this can translate into clinical applications. † The Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the Stroke Genetics Network N= number of participants; n.a.= not available; IS= Ischemic stroke; CE-IS= Cardioembolic ischemic stroke; SD= standard deviation; * More detailed descriptions of the composition of replication studies can be found in the appendix; † follow-up samples are from large artery ischemic stroke (first line) and small artery ischemic stroke (second line) for SiGN, METASTROKE, HVH1, and CADISP (TOAST subtyping) ; ǂ mean age of controls in the SiGN and CADISP study is not available as they were obtained from anonymous genotype databases Only associations with the lead SNP in each locus are shown in this table, the full set of genetic associations at p < 5×10 -6 is presented in supplementary table 7; All results are presented with respect to the minor allele as coded allele; MA= Minor allele; MAF= Minor allele frequency; HR= Hazards ratio; * mean value of imputation quality across studies; ƚ Chromosome positions with respect to NCBI built 37; ǂ number of variants reaching p < 5×10 -6 in the locus; † p-value after genomic control; ‡ Direction refers to direction of effect size with respect to the minor allele; ǁ Heterogeneity I 2 , ranges between 0 to 100, higher values suggesting more heterogeneity; § P-value for heterogeneity, calculated using the Cochran's Q test 
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